Core Viewpoint - Huajian Medical (01931) has announced a strategic partnership with Renhe Pharmaceutical (000650.SZ) to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in the implementation of its "ETHK blockchain financial ecosystem strategy" [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical signifies a new phase in the large-scale implementation and value realization of the "ETHK" blockchain financial ecosystem strategy [1] - This partnership serves as a benchmark case for the innovative "ETHK global RWA exchange" business model, aiming to create a replicable model that validates the feasibility and potential of this innovation [1] Group 2: Vision and Mission - The company believes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The goal is to empower classic national brands like Renhe Pharmaceutical to achieve digital transformation and promote successful ecological models across various industries, contributing to national industrial upgrades and the development of the digital economy [2] Group 3: Future Outlook - The board is confident that this strong alliance will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - The company aims to ensure the successful launch and stable operation of the world's first OTC RWA exchange through close collaboration with Renhe Pharmaceutical, leveraging both parties' resources [2]

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first vertical RWA exchange focused on the OTC sector in the United States, marking a significant step in Huajian's ETHK blockchain financial ecosystem strategy [1][2] Group 1: Strategic Collaboration - The collaboration with Renhe Pharmaceutical represents a key milestone in the implementation of Huajian's ETHK blockchain financial ecosystem strategy and the innovative "ETHK global RWA exchange" business model [1] - This partnership is intended to create a replicable model that validates the feasibility and potential of the innovative approach [1] Group 2: Commitment to Economic Development - Huajian Medical emphasizes that the ultimate mission of financial technology is to serve the real economy and create inclusive value, which this collaboration exemplifies [2] - The company aims to leverage technology to assist classic national brands like Renhe Pharmaceutical in their digital transformation, promoting successful ecological models across various industries [2] Group 3: Future Growth and Synergy - The board believes that this collaboration will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [2] - Huajian Medical plans to work closely with Renhe Pharmaceutical to ensure the successful launch and stable operation of the world's first OTC RWA exchange, aiming for high standards and quality [2]

Group 1 - The core viewpoint of the news is that Huajian Medical and Renhe Pharmaceutical have established a strategic partnership to create the world's first specialized trading platform for over-the-counter (OTC) real-world assets (RWA) [1][2] - The platform will adhere to securities-level standards and aims to provide an efficient, transparent, and compliant digital trading venue for intangible assets and product rights in the OTC industry, addressing a critical gap in the global market [1][2] - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a significant role in industry policy discussions and standard-setting, leveraging its competitive position in the Chinese OTC market to lead industry development [1] Group 2 - This strategic cooperation marks a new phase for the "ETHK" blockchain financial ecosystem strategy, showcasing the innovative "ETHK global RWA trading platform" model on a global stage [2] - The collaboration reflects the company's commitment to using cutting-edge technology and rigorous compliance practices to build an open and empowering digital financial ecosystem [2] - The partnership aims to facilitate the digital transformation of classic national brands like Renhe Pharmaceutical, contributing to national industrial upgrades and the development of the digital economy [2] Group 3 - The board believes that this collaboration will generate significant synergies, positively impacting the strategic transformation and value reassessment of both companies [3] - The companies will work closely to ensure the successful launch and stable operation of the world's first OTC RWA trading platform, leveraging their combined resources [3]

Core Viewpoint - The strategic partnership between Huajian Medical and Renhe Pharmaceutical aims to establish the world's first specialized trading platform for over-the-counter (OTC) real-world assets (RWA), addressing a significant gap in the global market [1][2]. Group 1: Strategic Collaboration - The collaboration signifies a new phase in Huajian Medical's "ETHK" blockchain financial ecosystem strategy, marking the global debut of its innovative "ETHK Global RWA Exchange" business model [2]. - Renhe Pharmaceutical, as the president unit of the China OTC Association, plays a crucial role in industry policy discussions and standard-setting, leveraging its strong market position to lead the development of the OTC sector [1][2]. Group 2: Goals and Vision - The partnership reflects the commitment to create a transparent, efficient, and compliant digital trading platform for intangible assets and product rights in the OTC industry, ultimately serving the broader goal of enhancing the digital economy and national industrial upgrades [2]. - The collaboration is expected to generate significant synergies, driving strategic transformation and value reassessment for both companies, while ensuring the successful launch and operation of the OTC RWA exchange [3].

Group 1 - The company has announced a strategic partnership with Renhe Pharmaceutical's wholly-owned subsidiary, Renhe International, to establish the world's first vertical RWA exchange focused on the OTC (over-the-counter) drug sector in the United States [1]

與 仁 和 藥 業（000650.SZ） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 IVD Medical Holding Limited 華檢醫療控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1931） 全資附屬公司仁和國際達成重大戰略合作 與 仁 和 藥 業（000650.SZ）間 接 全 資 附 屬 公 司 仁 和 國 際 達 成 重 大 戰 略 合 作，於 美 國 共 同 籌 建 全 球 首 家 非 處 方 藥（OTC）垂 直 領 域RWA交 易 所。 本 公 告 乃 由 華 檢 醫 療 控 股 有 限 公 司（「本公司」或「華檢醫療」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，旨 在 向 股 東 及 潛 在 投 資 者 提 供 本 集 團 業 務 發 展 的 最 新 資 料。 一、前 言：ETHK生態戰略的系統性深化 茲提述本公司日期為2025年 ...

Core Viewpoint - Huajian Medical is undergoing a strategic transformation from a medical enterprise to a builder of a blockchain-based financial ecosystem, marking a significant shift in its business focus towards digital industry technology infrastructure [3][4]. Group 1: Strategic Transformation - The establishment of joint ventures ETHK Inc and ETHK HOLDINGS LIMITED signifies a well-planned shift in Huajian Medical's strategy, focusing on developing a decentralized financial platform and integrating digital industry investments [3][4]. - The new branding reflects this transformation, with the company changing its name to ETHK Labs Inc, indicating a commitment to digital technology [4]. Group 2: Wealth Creation - The ETHK ecosystem aims to facilitate the globalization of Chinese assets, providing a one-stop investment platform for global capital [5]. - The strategic framework includes five pillars: robust technical infrastructure, diverse financial products, sustainable business models, global compliance frameworks, and seamless user experiences [5]. Group 3: Strategic Elevation - Huajian Medical's strategy aligns with national policies promoting the marketization of intellectual property and technological financial innovation, responding to government initiatives [6]. - Market data supports this transition, with significant growth projected in the Real World Asset (RWA) market, indicating a strong demand for asset tokenization [6]. Group 4: Value Creation - The ETHK ecosystem enhances China's international pricing power for assets and supports the internationalization of the Renminbi, aligning with Hong Kong's digital financial center strategy [8]. - The initiative lowers the barriers for asset digitization, providing new financing avenues for high-tech enterprises and promoting inclusive finance by allowing ordinary investors to participate in top-tier asset investments [9]. - Huajian Medical's holdings in Ethereum and substantial cryptocurrency budget provide dual value propositions for investors, combining stable cash flow from traditional medical operations with the growth potential of digital assets [9].

"不谋全局者，不足谋一域；不谋万世者，不足谋一时。"在全球金融与科技深度交织的当下，资本市场 早已不是单一维度的竞技场，而是一个跨越边界、重塑秩序的超级舞台。谁能率先找到新的价值锚点， 谁就有机会在这场浪潮中掌握主动权。 9月14日，华检医疗(01931)的一纸公告，犹如平静湖面投入的一颗巨石，瞬间激起市场的涟漪与讨论。 公告显示，华检医疗将携手ETHK Group共同投资设立两家新公司：ETHK INC与ETHK HOLDINGS LIMITED，同时将公司英文名称由"IVD Medical Holding Limited"更名为"ETHK Labs Inc."，同时将中文 双重外文名称由"华检医疗控股有限公司"调整为"华检数字产业集团有限公司"。 华检医疗9月14日公告 乍看之下，这似乎只是一次常规的品牌升级与合资动作，但若拨开表层，便会发现这更像是一场跨越行 业与国界的价值重构。它释放的不仅是名称上的变化，更是医药产业与链上金融生态深度融合的信号; 它承载的不仅是企业战略的升级，更预示着中国优质资产"链上出海"的全新尝试。 问题是：华检医疗为何选择在此刻动作频频?这两家合资公司的设立，又将如何重塑全球价 ...

Core Viewpoint - The announcement by Huajian Medical on September 14 signifies a strategic shift towards integrating the pharmaceutical industry with blockchain finance, indicating a new attempt for Chinese quality assets to go global [1][5]. Group 1: Company Strategy - Huajian Medical is transitioning to focus on digital industries and blockchain finance to create new growth avenues and enhance long-term shareholder value [6]. - The rebranding to "ETHK Labs Inc." reflects the company's new positioning as a key technology and infrastructure provider within the ETHK blockchain financial ecosystem [6][11]. - The establishment of ETHK INC and ETHK HOLDINGS LIMITED aims to develop a decentralized financial platform and serve as an investment and acquisition hub for digital industries [7][11]. Group 2: Global Asset Tokenization - Huajian Medical's strategy includes exploring the tokenization of global assets, particularly focusing on the tokenization of equity assets, which allows for efficient and compliant global financing and value discovery [9]. - The initiative aims to convert research outcomes and intellectual property into tradable digital assets, broadening financing channels for companies [9]. Group 3: Compliance and Security - The joint venture emphasizes compliance and security, seeking relevant financial and payment licenses globally, and establishing a comprehensive compliance framework [10]. - The framework includes KYC, AML, and CFT procedures, along with risk management tools to ensure the secure circulation of innovative assets on the blockchain [10]. Group 4: Strategic Significance - The collaboration with ETHK Group represents a significant upgrade in Huajian Medical's strategy, aligning with the global trend of financial asset digitization and blockchain integration [11]. - This strategic layout provides a broader platform for quality assets and diverse investment opportunities while ensuring safety through a strict compliance framework [11]. Group 5: Future Considerations - The development of the blockchain financial ecosystem is still in its early stages, facing challenges in technology, regulation, and market perception [13]. - Key questions include how to overcome technical barriers, establish a unified regulatory framework, and enhance market participants' understanding of blockchain finance [13].

Core Viewpoint - Huajian Medical is undergoing a strategic transformation from a medical enterprise to a builder of a blockchain-based financial ecosystem, marking a significant shift in its business focus towards digital industry technology infrastructure [4][5]. Group 1: Strategic Transformation - The company has announced a partnership with ETHK Group to establish two new companies, ETHK Inc and ETHK HOLDINGS LIMITED, focusing on decentralized financial platforms and digital industry investments [1][4]. - The rebranding reflects this shift, changing its English name from "IVD Medical Holding Limited" to "ETHK Labs Inc." and its Chinese name to "华检数字产业集团有限公司" [1][4]. - The new strategy aims to create a safe, efficient, compliant, and open decentralized financial platform under the "ETHK" brand [4]. Group 2: Global Asset Empowerment - The ETHK ecosystem is designed to facilitate the globalization of Chinese assets, providing a one-stop investment platform for global capital [6]. - The strategic framework includes five pillars: robust technical infrastructure, diverse financial products, sustainable business models, global compliance frameworks, and seamless user experiences [6]. - This approach addresses key pain points in the globalization of Chinese assets, such as limited financing channels and low cross-border flow efficiency [6]. Group 3: Financial Infrastructure for National Benefit - The strategic upgrade aligns with national policies promoting the marketization of intellectual property and innovation in technology finance [7]. - The ETHK strategy is positioned to enhance the international pricing power of Chinese assets and support the internationalization of the Renminbi [9]. - Market data indicates a significant growth potential in the tokenized asset market, with predictions of a global market size reaching $16.1 trillion by 2030 [7]. Group 4: Value Creation Paradigm - The new positioning reflects a thoughtful strategic choice, aiming to create value for various stakeholders, including the nation, industry, society, and investors [9]. - The ETHK ecosystem lowers the barriers for asset digitization, providing new financing avenues for high-tech enterprises and promoting inclusive finance [9]. - The company's stock performance has shown strong investor support, with shares rising from HKD 2 to HKD 10.44 since July, indicating confidence in the strategic direction [8].